BARDA Director Departs Post Overseeing COVID-19 Vaccine Efforts

Rick Bright will no longer head the Biomedical Advanced Research and Development Authority and will instead work at the National Institutes of Health on diagnostics for SARS-CoV-2 infection.

Written byJef Akst
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: Former BARDA Director Rick Bright (center) with National Institute of Allergy and Infectious Diseases Director Anthony Fauci (left) and Marilyn Serafini, former president and co-CEO of the Alliance for Health Reform
WIKIMEDIA, ALLIANCE FOR HEALTH POLICY

Update (August 9, 2021): Rick Bright will be compensated for “emotional stress and reputational damage” following the settlement of his whistleblower complaint against the federal government, though the details of the agreement remain undisclosed, The New York Times reports. Bright claims that the administration of former President Donald Trump put “politics and cronyism ahead of science” and removed him from his position overseeing COVID-19 vaccine development efforts because he pushed for more research into the anti-malaria drug hydroxychloroquine before issuing an emergency use authorization for its use for COVID-19. The Times reports that the Office of Special Counsel is still investigating those allegations.

Update (May 8): Rick Bright’s lawyers announced that the federal agency ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies